ATE374031T1 - Stabile augentropfen enthaltend latanoprost als wirkstoff - Google Patents

Stabile augentropfen enthaltend latanoprost als wirkstoff

Info

Publication number
ATE374031T1
ATE374031T1 AT03795230T AT03795230T ATE374031T1 AT E374031 T1 ATE374031 T1 AT E374031T1 AT 03795230 T AT03795230 T AT 03795230T AT 03795230 T AT03795230 T AT 03795230T AT E374031 T1 ATE374031 T1 AT E374031T1
Authority
AT
Austria
Prior art keywords
active ingredient
eye drops
latanoprost
drops containing
containing latanoprost
Prior art date
Application number
AT03795230T
Other languages
English (en)
Inventor
Hiroyuki Asada
Akio Kimura
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE374031T1 publication Critical patent/ATE374031T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03795230T 2002-08-23 2003-08-22 Stabile augentropfen enthaltend latanoprost als wirkstoff ATE374031T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002243955 2002-08-23
JP2002336242 2002-11-20

Publications (1)

Publication Number Publication Date
ATE374031T1 true ATE374031T1 (de) 2007-10-15

Family

ID=31996094

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03795230T ATE374031T1 (de) 2002-08-23 2003-08-22 Stabile augentropfen enthaltend latanoprost als wirkstoff

Country Status (12)

Country Link
US (2) US20050228048A1 (de)
EP (1) EP1532981B1 (de)
KR (2) KR101027454B1 (de)
CN (2) CN100361661C (de)
AT (1) ATE374031T1 (de)
AU (1) AU2003262268A1 (de)
CA (1) CA2496540C (de)
DE (1) DE60316574T2 (de)
DK (1) DK1532981T3 (de)
ES (1) ES2294361T3 (de)
PT (1) PT1532981E (de)
WO (1) WO2004024164A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2498233C (en) * 2002-09-09 2012-08-14 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
EP1655021B1 (de) 2004-11-09 2008-10-29 Novagali Pharma SA Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
US8030349B2 (en) 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
ES2327775T3 (es) * 2005-12-09 2009-11-03 Teva Pharmaceutical Industries, Ltd. Dispersiones y soluciones acuosas de compuestos dificiles de disolver y procedimientos para su preparacion.
EP1985298A1 (de) 2007-04-24 2008-10-29 Azad Pharma AG Prostaglandinhaltige Öl-in-Wasser-Emulsionen für das Auge
US8673937B2 (en) * 2008-04-23 2014-03-18 Otsuka Pharmaceutical Co., Ltd. Eye-drop preparation and use thereof
US10463677B2 (en) * 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
EP2228058A1 (de) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
EP2389939A1 (de) 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
CN110721260A (zh) * 2019-10-29 2020-01-24 深圳市瑞霖医药有限公司 一种新型拉坦前列素滴眼液

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU684115B2 (en) * 1993-12-27 1997-12-04 Mitsubishi Chemical Corporation Ophthalmic suspension containing diflupredonate
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AU7680096A (en) * 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
JP3480549B2 (ja) * 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
KR100508227B1 (ko) * 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
CA2295512C (en) * 1998-07-14 2009-05-26 Alcon Laboratories, Inc. Prostaglandin product
JP2001081048A (ja) * 1999-09-10 2001-03-27 Wakamoto Pharmaceut Co Ltd 眼圧降下剤
JP4757970B2 (ja) * 1999-10-14 2011-08-24 久光製薬株式会社 点眼剤組成物
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
PT1321144E (pt) * 2000-09-13 2011-03-10 Santen Pharmaceutical Co Ltd Colírio
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
CA2498233C (en) * 2002-09-09 2012-08-14 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient

Also Published As

Publication number Publication date
CA2496540A1 (en) 2004-03-25
KR20050038624A (ko) 2005-04-27
CN100591333C (zh) 2010-02-24
WO2004024164A1 (ja) 2004-03-25
US20110118348A1 (en) 2011-05-19
US20050228048A1 (en) 2005-10-13
CN1684688A (zh) 2005-10-19
PT1532981E (pt) 2007-12-12
KR101027454B1 (ko) 2011-04-06
EP1532981A1 (de) 2005-05-25
DK1532981T3 (da) 2008-01-28
KR20100132557A (ko) 2010-12-17
CA2496540C (en) 2011-01-25
EP1532981B1 (de) 2007-09-26
EP1532981A4 (de) 2005-10-12
CN101023927A (zh) 2007-08-29
ES2294361T3 (es) 2008-04-01
CN100361661C (zh) 2008-01-16
AU2003262268A1 (en) 2004-04-30
DE60316574D1 (de) 2007-11-08
DE60316574T2 (de) 2008-07-03

Similar Documents

Publication Publication Date Title
DE60316574D1 (de) Stabile augentropfen enthaltend latanoprost als wirkstoff
MXPA03011947A (es) Formulaciones de olopatidina para administracion topica.
GT199900072A (es) Jarabe antihistaminico estabilizado.
BR0317421A (pt) Géis de fase única não-aquosa estável e formulações destes para liberação a partir de um dispositivo implantável
BR0307702A (pt) Formulações de solução contendo anticorpo
HU9403350D0 (en) Remedy for glaucoma
DE60208494D1 (de) Herzfrequenzüberwachungsgerät
ATE503827T1 (de) Optische aufheller, deren herstellung und verwendung
DE50204946D1 (de) Dermal applizierbare flüssige formulierungen zur bekämpfung von parasitierenden insekten an tieren
ATE273033T1 (de) Stabilisierte ophthalmische wasserstoffperoxidlösung
CY1108593T1 (el) Συμπυκνωμενο υδατικο διαλυμα αμβροξολης
ATE354622T1 (de) Flüssigkristallines medium
NO20025081L (no) Stabilt flytende preparat
ZA200509222B (en) Stable, aqueous solution of human erythropoietin, not containing serum albumin
DK1692092T3 (da) Anvendelse af bis-aminer til forstærkning af den antimikrobielle aktivitet af vandige sammensætninger
ATE396743T1 (de) Stabile elektrolytlösungen enthaltend taurolidin
DK534087A (da) Desinfektionsmiddel indeholdende en stabiliseret hydrogenperoxidoploesning til desinfektion af bloede kontaktlinser
BR0207725A (pt) Promotores do crescimento e/ou da diferenciação de células-tronco hematopoiéticas e/ou progenitores hematopoiéticos
TWI263794B (en) Optical system
EP1304325A4 (de) Derivate des 5-(m-cyanobenzylamino)pyrazols
RU2006123317A (ru) Состав раствора эритропоэтина
AU2001242398A1 (en) Contact lens treating method and composition
ES2195309T3 (es) Derivados de tetrahidrofurano.
KR960020688A (ko) 안정화된 농약 조성물
ATE500730T1 (de) Herbizidzusammensetzungen und ihre verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1532981

Country of ref document: EP